# Royalty Pharma plc (RPRX) FY2024 Annual Balance Sheet

- Company: Royalty Pharma plc (RPRX)
- Period: As of 2024-12-31
- Filing: FY2024 10-K, filed 2025-02-12, accession number 0001802768-25-000010
- Page: https://plicit.ai/financials/rprx/fy2024-annual-balance-sheet
- Chart image: https://plicit.ai/charts/rprx-fy2024-annual-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2024-12-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 18,222,715,000 US dollars
- **Current assets**: 1,802,139,000 US dollars
- **Non-current assets**: 16,420,576,000 US dollars
- **Liabilities**: 7,880,349,000 US dollars
- **Current liabilities**: 1,253,616,000 US dollars
- **Non-current liabilities**: 6,626,733,000 US dollars
- **Equity**: 10,342,366,000 US dollars
- **Noncontrolling interest**: 3,395,785,000 US dollars. Included in consolidated equity; this amount is not added again.
- **Cash and cash equivalents**: 929,026,000 US dollars
- **Financial royalty assets**: 783,770,000 US dollars
- **Available for sale debt securities**: 58,200,000 US dollars
- **Other royalty income receivable**: 26,956,000 US dollars
- **Other current assets**: 4,187,000 US dollars
- **Financial royalty assets, net**: 15,127,158,000 US dollars
- **Available for sale debt securities**: 693,500,000 US dollars
- **Equity method investments**: 379,424,000 US dollars
- **Equity securities**: 186,960,000 US dollars
- **Other assets**: 33,534,000 US dollars
- **Current portion of long-term debt**: 997,773,000 US dollars
- **Interest payable**: 98,062,000 US dollars
- **Distributions payable to legacy non-controlling interests**: 75,811,000 US dollars
- **Other current liabilities**: 68,600,000 US dollars
- **Accounts payable and accrued expenses**: 13,370,000 US dollars
- **Long-term debt**: 6,614,653,000 US dollars
- **Other liabilities**: 12,080,000 US dollars
- **Additional paid-in capital**: 4,103,482,000 US dollars
- **Retained earnings**: 2,845,653,000 US dollars
- **Common stock - Class R Redeemable Shares**: 63,000 US dollars
- **Common stock - Class A Ordinary Shares**: 45,000 US dollars
- **Common stock - Class B Ordinary Shares**: 0 US dollars
- **Deferred shares, $0.000001 par value; issued and outstanding: 2024–392,255 and 2023–384,640**: 0 US dollars
- **Non-controlling interests**: 3,395,785,000 US dollars
- **Treasury interests**: negative 2,662,000 US dollars
- **Gross equity (calculated)**: 10,345,028,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.